Know When to Offer COVID-19 Post-Exposure Prophylaxis

September 2021

You’ll hear buzz about Regen-COV (casirivimab/imdevimab), the first med to PREVENT COVID-19...especially with cases on the rise.

This injectable monoclonal antibody combo blocks SARS-CoV-2 from entering cells.

It’s already authorized to TREAT mild to moderate COVID-19 in outpatients age 12 or older at high risk of severe illness. This includes patients with diabetes...age 65 or older...or even with a BMI over 25.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: MD includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

COVID-19 Know When to Offer COVID-19 Post-Exposure Prophylaxis
Vaginal Infections Save Brexafemme and Solosec as a Last Resort for Vaginal Infections
Statins Continue to Avoid Routine Statin Use in Pregnancy
Biosimilars Understand Why Semglee Will Be “Interchangeable” With Lantus
Fever Give Advice on Treating Fever in Children
Diabetes Have a Plan to Manage Diabetes Meds During a Fast
Hypertension Individualize Treatment for Resistant Hypertension
Infections Treat Foot Infections in Diabetes Based on Severity
ADHD Know How New Stimulant and Nonstimulant ADHD Meds Compare
Poisoning Know When High Acetylcysteine Doses May Be Used
Pumps Help Patients Admitted With a Pump
Cannabinoids Be Ready to Treat Cannabinoid Hyperemesis Syndrome

Know When to Offer COVID-19 Post-Exposure Prophylaxis

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents